La FDA ha approvato Talzenna per trattare il cancro alla prostata metastatico che non è resistente alla castrazione.

Published Date: 28 Jun 2023

The U. S. For metastatic HRR-mutated castration-resistant prostate cancer (mCRPC), the Food and Drug Administration has approved Talzenna (talazoparib) in combination with enzalutamide.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Radionuclide-Containing Combo Slows Metastatic Prostate Cancer, Improves Survival

2.

a cutting-edge cancer diagnostic tool.

3.

DBT Reduced Suicide Attempts in Adolescents with Bipolar Disorder.

4.

To automate the biopharmaceutical facilities of Reliance Life Sciences, ABB India has won the contract.

5.

In cases of locally advanced, potentially curable pancreatic cancer, a combination of drugs enhances the results of radiation therapy.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot